Alvotech (NASDAQ:ALVOW) Stock Price Up 4% – Should You Buy?

Alvotech (NASDAQ:ALVOW)’s stock price rose 4% during mid-day trading on Friday . The stock traded as high as $2.72 and last traded at $2.34. Approximately 7,115 shares were traded during mid-day trading, a decline of 38% from the average daily volume of 11,494 shares. The stock had previously closed at $2.25.

Alvotech Stock Up 4.0 %

The firm has a 50 day moving average price of $2.82 and a 200-day moving average price of $2.84.

Alvotech Company Profile

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass.